An IPMN, or intraductal papillary mucinous neoplasm, is a type of cyst that grows inside the ducts of the pancreas and produces a thick, gel-like substance called mucin. These growths are considered precancerous, meaning they start out benign but can slowly transform into pancreatic cancer over time through a series of genetic mutations. Most IPMNs are discovered by accident on imaging done for unrelated reasons, and the majority never become cancerous, but they require ongoing monitoring because some do.
How IPMNs Form in the Pancreas
Your pancreas has a network of ducts that carry digestive enzymes into the small intestine. IPMNs develop when cells lining these ducts begin growing abnormally, forming small finger-like projections (papillae) that jut into the duct and secrete mucin. That mucin can clog the duct system, causing the ducts or their smaller branches to swell with fluid. This is what creates the characteristic cyst-like appearance on imaging.
The abnormal cells originate from stem cells in the duct lining, and they can develop into several different cell types, each with its own behavior and risk profile. The progression from a harmless growth to cancer happens gradually through accumulating DNA damage, similar to how colon polyps can eventually become colon cancer. This slow timeline is what makes surveillance so effective: there’s usually a long window to catch concerning changes.
The Three Types of IPMN
IPMNs are classified by where they grow within the pancreatic duct system, and this location is the single biggest factor in determining cancer risk.
- Branch duct IPMN (BD-IPMN) grows in the smaller side branches of the pancreatic duct. These are the most common type and the least dangerous, with a malignancy risk ranging from about 1% to 25%. On imaging, they appear as one or more fluid-filled pockets connected to a normal-sized main duct.
- Main duct IPMN (MD-IPMN) involves the central pancreatic duct itself, causing it to widen significantly. These carry the highest cancer risk, between 33% and 85%, and are almost always recommended for surgical removal.
- Mixed-type IPMN affects both the main duct and its branches. The main duct is dilated to 5 mm or more, and there are cystic changes in the branch ducts as well. Mixed-type IPMNs behave like main duct IPMNs, with malignancy rates of 50% to 70%, so current guidelines also recommend surgery for these.
Who Gets IPMNs
IPMNs are most commonly diagnosed in people between the ages of 64 and 67, and they occur more frequently in men. Many are found incidentally when someone gets a CT scan or MRI for back pain, a car accident, or another unrelated issue. As imaging technology has improved and become more routine, IPMNs are being detected far more often than they were a few decades ago.
Most cases are sporadic, meaning they happen without a clear genetic cause. In rare instances, IPMNs occur alongside inherited cancer syndromes like familial adenomatous polyposis, Lynch syndrome, or Peutz-Jeghers syndrome. They can also occasionally appear in families with a history of pancreatic cancer, even without a known genetic syndrome.
Symptoms and How They’re Found
Many IPMNs cause no symptoms at all, especially smaller branch duct types. When symptoms do appear, the most common is upper abdominal pain or discomfort, reported in 70% to 80% of symptomatic patients. Other possible symptoms include weight loss (20% to 40%), nausea and vomiting (11% to 21%), back pain (around 10%), new-onset diabetes, and jaundice (yellowing of the skin and eyes).
Symptoms tend to develop when the mucin produced by the growth blocks the pancreatic duct, causing a backup of digestive enzymes. This can trigger episodes of pancreatitis, which is inflammation of the pancreas that causes severe abdominal pain. In some patients, recurrent pancreatitis is actually the first clue that leads to an IPMN diagnosis.
How IPMNs Are Diagnosed
The initial discovery usually happens on a CT scan or MRI. A specialized type of MRI called MRCP (magnetic resonance cholangiopancreatography) is particularly useful because it produces detailed images of the pancreatic duct system without requiring contrast dye or radiation. This allows doctors to see whether the cyst connects to the main duct, how large it is, and whether it contains any solid nodules growing along the inner wall, which are a red flag for cancer.
For a closer look, doctors may use endoscopic ultrasound (EUS), where a tiny ultrasound probe is passed through the mouth and stomach to sit right next to the pancreas. EUS can detect mural nodules and other internal features that CT and MRI might miss. During this procedure, fluid can be drawn from the cyst with a fine needle for analysis.
Cyst fluid testing helps confirm the diagnosis. A glucose level of 25 mg/dL or lower in the fluid is a strong indicator that the cyst is mucin-producing, with about 88% sensitivity and 91% specificity. Another marker called CEA, using a cutoff of 192 ng/mL or higher, can also point to a mucin-producing cyst, though it’s less accurate on its own.
Monitoring Low-Risk IPMNs
Most branch duct IPMNs don’t need surgery right away. Instead, they’re monitored with periodic imaging, typically MRI, to watch for growth or worrisome changes. The monitoring schedule depends on the cyst’s size.
After an initial follow-up scan at six months, current recommendations suggest imaging every 18 months for cysts smaller than 20 mm, every 12 months for cysts between 20 and 30 mm, and every 6 months for cysts 30 mm or larger. For people with small cysts (under 20 mm) that remain completely stable over five years of surveillance, monitoring may be stopped if they have a life expectancy of 10 years or less or would not be candidates for surgery.
The features that trigger concern during monitoring include rapid growth, the appearance of solid nodules inside the cyst, widening of the main pancreatic duct, or new symptoms like jaundice or pancreatitis. Any of these can shift the recommendation from watching to operating.
Surgery and Survival Outcomes
When surgery is recommended, it typically involves removing the portion of the pancreas that contains the IPMN. The specific operation depends on where the growth is located: a procedure on the head of the pancreas (Whipple procedure) for growths in that area, or removal of the tail for growths on the opposite end.
Outcomes depend almost entirely on whether the IPMN has become invasive cancer by the time it’s removed. For non-invasive IPMNs, including those classified as adenoma, borderline, or carcinoma in situ, the five-year survival rate after surgery is 94%. This is an excellent outcome and reflects how effective early intervention can be.
If the IPMN has already progressed to invasive cancer, the picture changes dramatically. Five-year survival drops to about 31%, which is similar to the 24% five-year survival seen in standard pancreatic cancer. This stark difference is the entire reason surveillance programs exist: the goal is to catch and remove IPMNs before they cross the line into invasion.
Living With an IPMN Diagnosis
Being told you have an IPMN can feel alarming, especially given its association with pancreatic cancer. In practice, most people with branch duct IPMNs will never need surgery and will never develop cancer from their cyst. The experience of living with an IPMN is primarily one of routine surveillance: periodic MRI scans, occasional clinic visits, and staying alert for new symptoms like unexplained weight loss, persistent abdominal pain, or jaundice.
People with IPMNs also have a slightly elevated risk of developing pancreatic cancer elsewhere in the pancreas, not just within the cyst itself. This is one reason surveillance continues even after a cyst has been stable for years, particularly in younger patients with a long life expectancy ahead of them.